샘플 요청 목록

 카트 문의
시장보고서
상품코드
1771611

백신 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 투여 경로별, 적응 질환별, 연령층별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route Of Administration (Oral), By Disease Indication (HPV, MMR), By Age Group (Adult), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

백신 시장 성장과 동향 :

Grand View Research의 최신 보고서에 따르면 세계의 백신 시장 규모는 2033년까지 1,519억 6,000만 달러에 이를 것으로 예측됩니다.

이 시장은 2025년부터 2033년까지 연평균 복합 성장률(CAGR) 7.8%를 나타낼 것으로 전망됩니다. 많은 새로운 백신이 개발되어 세계적으로 배포되게 되어, 그 결과, 수많은 인명이 구원되고, 다양한 질병이 예방되게 되었습니다.

또한, 백신 시장에는 백신에 대한 접근을 개선하고, 새로운 백신을 개발하고, 백신의 안전성을 확보하는 것을 목적으로 한 이니셔티브가 존재합니다. 예를 들어, COVAX는 COVID 백신에 대한 공정한 접근을 보장하는 것을 목표로 한 세계적 이니셔티브입니다.

2021년 기준 세계보건기구(WHO) 회원국에 백신을 공급하는 백신 제조업자는 90개가 넘지만, 공급은 여전히 다양한 전개 가능 기술과 세계의 리치를 가진 10개 미만의 제조업자에 크게 의존하고 있습니다. 미국에서는 2023년 후반에 COVID 백신 시장이 민영화될 가능성이 있다고 예상된 바 있습니다. 예를 들어, 모더나와 화이자 바이오엔텍은 각자의 mRNA 코로나 백신 가격이 1회 접종당 약 110-130달러로 인상될 수 있다고 발표했습니다.

백신 시장 하이라이트

  • 2024년의 백신 시장은 서브 유닛 백신이 44.30%의 점유율을 차지했고, 예측 기간 중에 급성장이 예상됩니다.
  • 백신의 투여에는 비경구 투여가 선호되기 때문에 이 부문은 2024년에 96.65%의 점유율로 백신 시장을 독점했습니다.
  • 바이러스성 질환 분야는 2023년에 63.79%의 점유율로 백신 시장을 독점했고, 그 주인은 COVID-19 백신입니다.
  • 2024년의 백신 시장에서는 성인이 55.73%의 점유율을 차지했습니다.
  • 2024년 백신 시장은 정부계 공급업체가 54.81%의 점유율을 차지했습니다.
  • 북미의 백신 시장은 예측 기간 중 가장 빠른 CAGR을 나타낼 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 시장 변수, 동향, 범위

  • 시장 세분화 및 범위
  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/보조시장 전망
  • 시장 동향과 전망
  • 시장 역학
    • 세계에서 예방접종의 중요성 증가
    • 만성질환과 감염증의 부담 증대
    • 백신 개발에 있어서의 기술의 진보
  • 시장 성장 억제요인 분석
    • 헬스케어 인프라의 부족
    • 예방 접종 비용
  • 비즈니스 환경 분석
    • SWOT 분석 : 요인별(정치·법률, 경제·기술)
    • Porter's Five Forces 분석
  • COVID-19의 영향 분석

제3장 유형의 비즈니스 분석

  • 유형 시장 점유율(2024년 및 2033년)
  • 부문 대시보드
  • 백신 시장 : 유형별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 서브 유닛 백신
    • 서브 유닛 백신 시장(2021-2033년)
    • 재조합 백신
    • 접합 백신
    • 톡소이드 백신
  • 비활성화
  • 생약독화
  • mRNA 백신
  • 바이러스 벡터 백신

제4장 투여 경로의 비즈니스 분석

  • 투여 경로 시장 점유율(2024년 및 2033년)
  • 부문 대시보드
  • 백신 시장 : 투여 경로별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 경구
  • 비경구
  • 비강

제5장 적응 질환의 비즈니스 분석

  • 적응 질환 시장 점유율(2024년 및 2033년)
  • 부문 대시보드
  • 백신 시장 : 적응 질환별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 바이러스성 질환
    • 바이러스성 질환 백신 시장(2021-2033년)
    • 간염
    • 인플루엔자
    • HPV
    • MMR
    • 로타바이러스
    • 대상포진
    • COVID-19
    • 기타
  • 박테리아 백신
    • 박테리아 백신 시장(2021-2033년)
    • 수막구균성 질환
    • 폐렴구균 질환
    • DPT
    • 기타
  • 암 백신
  • 알레르기 백신

제6장 연령대의 비즈니스 분석

  • 연령층 시장 점유율(2024년 및 2033년)
  • 부문 대시보드
  • 백신 시장 : 연령층별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 소아
  • 성인

제7장 유통 채널의 비즈니스 분석

  • 유통 채널 시장 점유율(2024년 및 2033년)
  • 부문 대시보드
  • 백신 시장 : 유통 채널별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 병원 및 약국
  • 정부 공급자
  • 기타

제8장 지역의 비즈니스 분석

  • 지역별 백신 시장 점유율(2024년 및 2033년)
  • 북미
    • 북미의 백신 시장(2021-2033년)
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 유럽의 백신 시장(2021-2033년)
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 아시아태평양의 백신 시장(2021-2033년)
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 라틴아메리카의 백신 시장(2021-2033년)
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 중동 및 아프리카의 백신 시장(2021-2033년)
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제9장 경쟁 구도

  • 참가 기업의 개요
  • 재무실적
  • 참가 기업
    • 마켓 리더
    • 백신 시장 점유율 분석(2023년)
    • 기업 프로파일
    • 전략 매핑
      • Serum Institute of India Pvt. Ltd.
      • Seqirus
      • Sanofi
      • GSK Plc.
      • Merck & Co. Inc.
      • Pfizer Inc.
      • Moderna Inc.
      • Sinovac
      • BioNTech SE
      • AstraZeneca
KTH

Vaccine Market Growth & Trends:

The global vaccine market size is expected to reach USD 151.96 billion by 2033, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.8% from 2025 to 2033. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Vaccine Market Report Highlights:

  • The subunit Vaccines segment dominated the vaccine market with a share of 44.30% in 2024 and is expected to experience rapid growth during the forecast period.
  • Parenteral administration is highly preferred for administering vaccines and hence the segment dominated the vaccine market with a share of 96.65% in 2024.
  • The viral diseases segment dominated the vaccine market with a share of 63.79% in 2023, majorly attributed to COVID-19 vaccines.
  • Adult accounted for a share of 55.73% in the vaccine market in 2024. Adult vaccination, including those for COVID-19, comprised 75% in terms of volume globally, while pediatric vaccines accounted for about 20%.
  • Government suppliers dominated the vaccine market in 2024 with a share of 54.81%.
  • North America vaccines market is estimated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Route of Administration
    • 1.2.3. Disease Indication
    • 1.2.4. Age Group
    • 1.2.5. Distribution Channel
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Market Variables, Trends, & Scope

  • 2.1. Market Segmentation and Scope
  • 2.2. Market Lineage Outlook
    • 2.2.1. Parent Market Outlook
    • 2.2.2. Related/Ancillary Market Outlook
  • 2.3. Market Trends and Outlook
  • 2.4. Market Dynamics
    • 2.4.1. Rise in the importance of immunization across the globe
    • 2.4.2. Growing Burden of Chronic and Infectious Diseases
    • 2.4.3. Technology advancements in the vaccination development
  • 2.5. Market Restraint Analysis
    • 2.5.1. Lack of healthcare infrastructure
    • 2.5.2. Cost of immunization
  • 2.6. Business Environment Analysis
    • 2.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 2.6.2. Porter's Five Forces Analysis
  • 2.7. COVID-19 Impact Analysis

Chapter 3. Type Business Analysis

  • 3.1. Type Market Share, 2024 & 2033
  • 3.2. Segment Dashboard
  • 3.3. Vaccines Market by Type Outlook
  • 3.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 3.5. Subunit Vaccines
    • 3.5.1. Vaccine Market for Subunit Vaccines, 2021 - 2033 (USD Billion)
    • 3.5.2. Recombinant vaccines
      • 3.5.2.1. Vaccine Market for Recombinant vaccines, 2021 - 2033 (USD Billion)
    • 3.5.3. Conjugate Vaccines
      • 3.5.3.1. Vaccine Market for Conjugate vaccines, 2021 - 2033 (USD Billion)
    • 3.5.4. Toxoid vaccines
      • 3.5.4.1. Vaccine Market for Toxoid vaccines, 2021 - 2033 (USD Billion)
  • 3.6. Inactivated
    • 3.6.1. Vaccine Market for Inactivated, 2021 - 2033 (USD Billion)
  • 3.7. Live Attenuated
    • 3.7.1. Vaccine Market for Live Attenuated, 2021 - 2033 (USD Billion)
  • 3.8. mRNA vaccines
    • 3.8.1. Vaccine Market for mRNA vaccines, 2021 - 2033 (USD Billion)
  • 3.9. Viral vector vaccines
    • 3.9.1. Vaccine Market for Viral vector vaccines, 2021 - 2033 (USD Billion)

Chapter 4. Route Of Administration Business Analysis

  • 4.1. Route of administration Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Vaccines Market by Route of administration Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Oral
    • 4.5.1. Vaccine Market for Oral, 2021 - 2033 (USD Billion)
  • 4.6. Parenteral
    • 4.6.1. Vaccine Market for Parenteral, 2021 - 2033 (USD Billion)
  • 4.7. Nasal
    • 4.7.1. Vaccine Market for Nasal, 2021 - 2033 (USD Billion)

Chapter 5. Disease Indication Business Analysis

  • 5.1. Disease Indication Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Vaccines Market by Disease Indication Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Viral Diseases
    • 5.5.1. Vaccine Market for Viral Diseases, 2021 - 2033 (USD Billion)
    • 5.5.2. Hepatitis
      • 5.5.2.1. Vaccine Market for Hepatitis, 2021 - 2033 (USD Billion)
    • 5.5.3. Influenza
      • 5.5.3.1. Vaccine Market for Influenza, 2021 - 2033 (USD Billion)
    • 5.5.4. HPV
      • 5.5.4.1. Vaccine Market for HPV, 2021 - 2033 (USD Billion)
    • 5.5.5. MMR
      • 5.5.5.1. Vaccine Market for MMR, 2021 - 2033 (USD Billion)
    • 5.5.6. Rotavirus
      • 5.5.6.1. Vaccine Market for Rotavirus, 2021 - 2033 (USD Billion)
    • 5.5.7. Herpes Zoster
      • 5.5.7.1. Vaccine Market for Herpes Zoster, 2021 - 2033 (USD Billion)
    • 5.5.8. COVID-19
      • 5.5.8.1. Vaccine Market for Covid-19, 2021 - 2033 (USD Billion)
    • 5.5.9. Others
      • 5.5.9.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)
  • 5.6. Bacterial Vaccines
    • 5.6.1. Vaccine Market for Bacterial Vaccines, 2021 - 2033 (USD Billion)
    • 5.6.2. Meningococcal Diseases
      • 5.6.2.1. Vaccine Market for Meningococcal Diseases, 2021 - 2033 (USD Billion)
    • 5.6.3. Pneumococcal Diseases
      • 5.6.3.1. Vaccine Market for Pneumococcal Diseases, 2021 - 2033 (USD Billion)
    • 5.6.4. DPT
      • 5.6.4.1. Vaccine Market for DPT, 2021 - 2033 (USD Billion)
    • 5.6.5. Others
      • 5.6.5.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)
  • 5.7. Cancer Vaccines
    • 5.7.1. Vaccine Market for Cancer Vaccines, 2021 - 2033 (USD Billion)
  • 5.8. Allergy Vaccines
    • 5.8.1. Vaccine Market for Allergy Vaccines, 2021 - 2033 (USD Billion)

Chapter 6. Age Group Business Analysis

  • 6.1. Age Group Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Vaccines Market by Age Group Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Pediatric
    • 6.5.1. Vaccine Market for Pediatric, 2021 - 2033 (USD Billion)
  • 6.6. Adult
    • 6.6.1. Vaccine Market for Adult, 2021 - 2033 (USD Billion)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Vaccines Market by Distribution Channel Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Hospital & Retail Pharmacies
    • 7.5.1. Vaccine Market for Hospital & Retail Pharmacies, 2021 - 2033 (USD Billion)
  • 7.6. Government Suppliers
    • 7.6.1. Vaccine Market for Government Suppliers 2021 - 2033 (USD Billion)
  • 7.7. Others
    • 7.7.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)

Chapter 8. Regional Business Analysis

  • 8.1. Vaccine Market Share By Region, 2024 & 2033
  • 8.2. North America
    • 8.2.1. North America Vaccines Market 2021 - 2033 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Vaccine Market 2021 - 2033 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Vaccine Market 2021 - 2033 (USD Billion)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico Vaccine Market 2021 - 2033 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Vaccines Market 2021 - 2033 (USD Billion)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Vaccine Market 2021 - 2033 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Vaccine Market, 2021 - 2033 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Vaccine Market 2021 - 2033 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Vaccine Market, 2021 - 2033 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Vaccine Market 2021 - 2033 (USD Billion)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Argentina Vaccine Market 2021 - 2033 (USD Billion)
  • 8.6. MEA
    • 8.6.1. MEA Vaccine Market, 2021 - 2033 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Vaccine Market 2021 - 2033 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Vaccine Market 2021 - 2033 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Vaccine Market 2021 - 2033 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Vaccine Market 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Vaccine Market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Serum Institute of India Pvt. Ltd.
        • 9.3.3.1.1. Company Overview
        • 9.3.3.1.2. Financial Performance
        • 9.3.3.1.3. Product Benchmarking
        • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Seqirus
        • 9.3.3.2.1. Company Overview
        • 9.3.3.2.2. Financial Performance
        • 9.3.3.2.3. Product Benchmarking
        • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Sanofi
        • 9.3.3.3.1. Company Overview
        • 9.3.3.3.2. Financial Performance
        • 9.3.3.3.3. Product Benchmarking
        • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. GSK Plc.
        • 9.3.3.4.1. Company Overview
        • 9.3.3.4.2. Financial Performance
        • 9.3.3.4.3. Product Benchmarking
        • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. Merck & Co., Inc.
        • 9.3.3.5.1. Company Overview
        • 9.3.3.5.2. Financial Performance
        • 9.3.3.5.3. Product Benchmarking
        • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Pfizer Inc.
        • 9.3.3.6.1. Company Overview
        • 9.3.3.6.2. Financial Performance
        • 9.3.3.6.3. Product Benchmarking
        • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Moderna Inc.
        • 9.3.3.7.1. Company Overview
        • 9.3.3.7.2. Financial Performance
        • 9.3.3.7.3. Product Benchmarking
        • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Sinovac
        • 9.3.3.8.1. Company Overview
        • 9.3.3.8.2. Financial Performance
        • 9.3.3.8.3. Product Benchmarking
        • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. BioNTech SE
        • 9.3.3.9.1. Company Overview
        • 9.3.3.9.2. Financial Performance
        • 9.3.3.9.3. Product Benchmarking
        • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. AstraZeneca
        • 9.3.3.10.1. Company Overview
        • 9.3.3.10.2. Financial Performance
        • 9.3.3.10.3. Product Benchmarking
        • 9.3.3.10.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Product/Service Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제